<DOC>
	<DOCNO>NCT00045422</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Combining interferon alfa imatinib mesylate may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine interferon alfa imatinib mesylate treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Interferon Alfa Imatinib Mesylate Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether interferon alfa combination imatinib mesylate add hematologic , cytogenetic , molecular response rate patient chronic phase chronic myelogenous leukemia newly diagnose achieve complete cytogenetic response imatinib mesylate alone . OUTLINE : Patients receive oral imatinib mesylate ( STI-571 ) daily 9 month . At 9 month , patient 35 % Philadelphia chromosome-positive ( Ph+ ) cell bone marrow receive oral STI-571 twice daily 3 month . At 12 month , patient 35 % Ph+ cell bone marrow receive oral STI-571 daily interferon alfa subcutaneously daily . Treatment continue least 1 year absence disease progression unacceptable toxicity . Patients appropriate HLA-matched donor may choose bone marrow transplantation time study . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 80 patient ( 60 without HLA-matched donor 20 HLA-matched donor ) accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myelogenous leukemia Cytogenetically confirm Philadelphia chromosomepositive disease variant ( 9 ; 22 ) No secondary chromosomal abnormalities No 10 % blast bone marrow Newly diagnose OR Received prior imatinib mesylate single agent past 9 month without achieve complete cytogenetic response No evidence extramedullary involvement except node , liver , spleen PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 03 Life expectancy Not specify Hematopoietic Platelet count great 100,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN INR great 1.5 time ULN* PTT great 1.5 time ULN* NOTE : * Except patient anticoagulant Renal Creatinine great 2 time ULN Other Considered potentially reliable No history noncompliance medical regimens No active malignancy require chemotherapy radiotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy No prior interferon therapy No prior stem cell bone marrow transplantation Chemotherapy No prior chemotherapy ( except hydroxyurea and/or anagrelide control count ) Endocrine therapy Not specify Radiotherapy Not specify Surgery At least 4 week since prior major surgery recover Other No concurrent grapefruit juice grapefruit product No concurrent warfarin Concurrent lowmolecular weight heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>